Evidence map›Paper›PMID 35390294›Full record

SynthesisThe Lancet. Infectious diseases2022

Invasive group A streptococcal disease in pregnant women and young children: a systematic review and meta-analysis.

Emma Sherwood, Stefania Vergnano, Isona Kakuchi, Michael G Bruce, Suman Chaurasia, Samara David, Angela Dramowski, Scarlett Georges, Rebecca Guy, Theresa Lamagni and 10 more

Abstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in The Lancet. Infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Frontiers in public health · 2023
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Polish journal of microbiology · 2025
    Article
  10. Article
  11. Genomic interrogation of invasive group AThe Lancet regional health. Western Pacific · 2025
    Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Emma SherwoodEpidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK. Electronic address: emmasherwood@nhs.net.
Stefania VergnanoPaediatric Infectious Diseases, Bristol Royal Hospital for Children, University Hospitals Bristol NHS, Bristol, UK.
Isona KakuchiPaediatric Infectious Diseases, Bristol Royal Hospital for Children, University Hospitals Bristol NHS, Bristol, UK.
Michael G BruceCenters for Disease Control and Prevention, Arctic Investigations Program, Anchorage, Alaska, USA.
Suman ChaurasiaDepartment of Paediatrics, All India Institute of Medical Sciences, New Delhi, India.
Samara DavidBritish Columbia Centre for Disease Control, University of British Columbia, BC, Canada.
Angela DramowskiDepartment of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Scarlett GeorgesInfectious Diseases Department, Santé Publique France, French National Public Health Agency, St Maurice, France.
Rebecca GuyNational Infection Service, UK Health Security Agency, London, UK.
Theresa LamagniNational Infection Service, UK Health Security Agency, London, UK.
Daniel Levy-BruhlInfectious Diseases Department, Santé Publique France, French National Public Health Agency, St Maurice, France.
Outi LyytikäinenNational Institute for Health and Welfare, Department of Health Security, Infectious Disease Control and Vaccinations Unit, Helsinki, Finland.
Monika NausBritish Columbia Centre for Disease Control, University of British Columbia, BC, Canada.
Jennifer Onukwube OkaroCenters for Disease Control and Prevention, Atlanta, GA, USA.
Oddvar OppegaardDepartment of Medicine, Haukeland University Hospital, Bergen, Norway.
Didrik F VestrheimDepartment of Vaccine Preventable Diseases, Norwegian Institute of Public Health, Oslo, Norway.
Tammy ZulzCenters for Disease Control and Prevention, Arctic Investigations Program, Anchorage, Alaska, USA.
Andrew C SteerMurdoch Children's Research Institute, Melbourne, VIC, Australia.
Chris A Van BenedenCenters for Disease Control and Prevention, Atlanta, GA, USA.
Anna C SealeEpidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.

Funding

Wellcome Trust 205184Wellcome Trust 205184/Z/16/Z
6 · The paper itself

Abstract

backgroundThe incidence of invasive disease caused by group A streptococcus (GAS) has increased in multiple countries in the past 15 years. However, despite these reports, to the best of our knowledge, no systematic reviews and combined estimates of the incidence of invasive GAS have been done in key high-risk groups. To address this, we estimated the incidence of invasive GAS disease, including death and disability outcomes, among two high-risk groups-namely, pregnant women and children younger than 5 years.

methodsWe did a systematic review and meta-analyses on invasive GAS outcomes, including incidence, case fatality risks, and neurodevelopmental impairment risk, among pregnant women, neonates (younger than 28 days), infants (younger than 1 year), and children (younger than 5 years) worldwide and by income region. We searched several databases for articles published from Jan 1, 2000, to June 3, 2020, for publications that reported invasive GAS outcomes, and we sought unpublished data from an investigator group of collaborators. We included studies with data on invasive GAS cases, defined as laboratory isolation of Streptococcus pyogenes from any normally sterile site, or isolation of S pyogenes from a non-sterile site in a patient with necrotising fasciitis or streptococcal toxic shock syndrome. For inclusion in pooled incidence estimates, studies had to report a population denominator, and for inclusion in pooled estimates of case fatality risk, studies had to report aggregate data on the outcome of interest and the total number of cases included as a denominator. We excluded studies focusing on groups at very high risk (eg, only preterm infants). We assessed heterogeneity with I

findingsOf the 950 published articles and 29 unpublished datasets identified, 20 studies (seven unpublished; 3829 cases of invasive GAS) from 12 countries provided sufficient data to be included in pooled estimates of outcomes. We did not identify studies reporting invasive GAS incidence among pregnant women in low-income and middle-income countries (LMICs) nor any reporting neurodevelopmental impairment after invasive GAS in LMICs. In nine studies from high-income countries (HICs) that reported invasive GAS in pregnancy and the post-partum period, invasive GAS incidence was 0·12 per 1000 livebirths (95% CI 0·11 to 0·14; I

interpretationWe found a substantial burden of invasive GAS among young children. In LMICs, little data were available for neonates and children and no data were available for pregnant women. Incidences of invasive GAS are likely to be underestimates, particularly in LMICs, due to low GAS surveillance. It is essential to improve available data to inform development of prevention and management strategies for invasive GAS.

fundingWellcome Trust.

Indexed as

Pregnant PeopleStreptococcal InfectionsChildChild, PreschoolFemaleHumansIncidenceInfantInfant, NewbornInfant, PrematurePregnancyStreptococcus pyogenes

Identifiers

PMID35390294
PMCPMC9217756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.